Breaking News Instant updates and real-time market news.

JNCE

Jounce Therapeutics

$4.10

-0.1 (-2.38%)

, TER

Teradyne

$48.09

1.26 (2.69%)

18:56
07/23/19
07/23
18:56
07/23/19
18:56

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Jounce (JNCE) up 35.7%... Teradyne (TER) up 17.5%... Edwards Lifesciences (EW) up 10.3%... Manhattan Associates (MANH) up 10.0%... Snap (SNAP) up 9.2%... Texas Instruments (TXN) up 6.4%... Old Line Bancshares (OLBK) up 5.2%... Carlisle (CSL) up 4.2%... Chipotle (CMG) up 3.3%... Canadian National (CNI) up 2.7%... Discover (DFS) up 2.3%... Navient (NAVI) up 1.8%. ALSO HIGHER: Wells Fargo (WFC) up 0.4% after raising dividend and boosting buyback. DOWN AFTER EARNINGS: iRobot (IRBT) down 17.0%... Robert Half (RHI) down 0.5%... Visa (V) down 0.3%. ALSO LOWER: Seatte Genetics (SGEN) down 3.8% after equity offering... Facebook (FB) down 1.7%, Twitter (TWTR) down 1.0%, Amazon (AMZN) down 1.2%, Alphabet (GOOG) down 1.0% after DoJ announced probe into competition stifling efforts by large tech firms. Movers as of 18:30ET.

JNCE

Jounce Therapeutics

$4.10

-0.1 (-2.38%)

TER

Teradyne

$48.09

1.26 (2.69%)

EW

Edwards Lifesciences

$195.47

1.55 (0.80%)

MANH

Manhattan Associates

$72.91

1.16 (1.62%)

SNAP

Snap

$14.85

0.71 (5.02%)

TXN

Texas Instruments

$120.05

1.89 (1.60%)

OLBK

Old Line Bancshares

$26.14

(0.00%)

CSL

Carlisle

$132.30

2.445 (1.88%)

CMG

Chipotle

$740.42

-1.88 (-0.25%)

CNI

Canadian National

$91.05

-0.07 (-0.08%)

DFS

Discover

$84.54

2.205 (2.68%)

NAVI

Navient

$13.71

0.27 (2.01%)

WFC

Wells Fargo

$47.20

0.7 (1.51%)

IRBT

iRobot

$89.64

-2.7 (-2.92%)

RHI

Robert Half

$58.81

1.45 (2.53%)

V

Visa

$180.89

0.34 (0.19%)

SGEN

Seattle Genetics

$75.88

-0.22 (-0.29%)

FB

Facebook

$202.38

0.06 (0.03%)

TWTR

Twitter

$37.90

0.32 (0.85%)

AMZN

Amazon.com

$1,994.44

8.51 (0.43%)

GOOG

Alphabet

$1,146.62

8.53 (0.75%)

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 03

    Aug

  • 08

    Aug

  • 21

    Aug

  • 04

    Sep

  • 05

    Sep

  • 09

    Sep

  • 11

    Sep

  • 23

    Sep

  • 25

    Sep

  • 12

    Oct

  • 15

    Oct

  • 27

    Oct

  • 13

    Nov

  • 24

    Jul

JNCE Jounce Therapeutics
$4.10

-0.1 (-2.38%)

11/13/18
JPMS
11/13/18
DOWNGRADE
JPMS
Underweight
Jounce Therapeutics downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov downgraded Jounce Therapeutics to Underweight from Neutral.
11/14/18
JPMS
11/14/18
DOWNGRADE
JPMS
Underweight
JPMorgan downgrades Jounce to Underweight on lack of catalysts
JPMorgan analyst Cory Kasimov last night downgraded Jounce Therapeutics to Underweight from Neutral without a price target. It may take the company some time to generate substantial enough clinical data to prompt investors to reengage, Kasimov tells investors in a research note following the company's Q3 results. While the company is well capitalized and has a compelling approach to drug development, Jounce shares could continue to be a relative underperformer given a lack of meaningful clinical catalysts, says the analyst.
08/13/18
HCWC
08/13/18
NO CHANGE
Target $13
HCWC
Buy
Jounce Therapeutics price target lowered to $13 from $19 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Jounce Therapeutics to $13 but keeps a Buy rating on the shares. The analyst sees limited near-term catalysts to drive investor sentiment, and he believes there remains "substantial clinical questions that need to be addressed before ICOS agonism comes back to the fore."
TER Teradyne
$48.09

1.26 (2.69%)

04/25/19
BARD
04/25/19
UPGRADE
BARD
Outperform
Teradyne upgraded to Outperform from Neutral at Baird
04/05/19
DADA
04/05/19
NO CHANGE
Target $40
DADA
Neutral
Teradyne's appointment of new CFO a 'benefit', says DA Davidson
DA Davidson analyst Thomas Diffely says the appointment of Sanjay Mehta as new CFO by Teradyne following the planned retirement of Gregory Beecher is a positive. The analyst notes that Mehta "inherits an efficient financial model and brings a solid resume of large company experience, including roles at Qualcomm and Nortell". Diffely is also keeping his Neutral rating and $40 price target on Teradyne, stating that its current risk-reward appears "balanced".
06/18/19
STFL
06/18/19
NO CHANGE
STFL
Buy
Semiconductor test equipment estimates lowered at Stifel
Stifel analyst Brian Chin said commentary directly from Huawei and its supply chain has further quantified the impact of recent trade restrictions and tariffs and with the "malaise in May now too acute to ignore" he has lowered his 2019 and 2020 revenue forecasts for semiconductor test equipment suppliers Teradyne (TER), Cohu (COHU) and FormFactor (FORM). However, he keeps Buy ratings on all three stocks as Chin thinks some of the near-term risk to estimates is already discounted and that a cyclical semi recovery "remains very much in play" for next year.
04/25/19
DADA
04/25/19
NO CHANGE
Target $48
DADA
Neutral
Teradyne price target raised to $48 from $40 at DA Davidson
DA Davidson analyst Thomas Diffely raised his price target on Teradyne (TER) to $48 after its Q1 earnings beat and the management's outlook forecasting Semiconductor Test business recovery in 2020. The analyst also cites the emerging 5G ramp and improvement in Apple (AAPL) demand next year, along with the benefits of the Industrial Automation being in the early innings of industry adoption, but keeps his Neutral rating on Teradyne shares given their recent price appreciation.
EW Edwards Lifesciences
$195.47

1.55 (0.80%)

04/15/19
FBCO
04/15/19
NO CHANGE
Target $221
FBCO
Outperform
Edwards Lifesciences price target raised to $221 from $189 at Credit Suisse
Credit Suisse analyst Matt Miksic raised his price target for Edwards Lifesciences to $221 from $189, while reiterating an Outperform rating on the shares. his bullish outlook is based in part on his view that the company does not yet reflect the low-risk expansion of the TAVR market, and investors appear likely to look past Q1 results toward evidence over the next few quarters of increased TAVR growth following the LR data.
04/24/19
JEFF
04/24/19
NO CHANGE
Target $210
JEFF
Buy
Edwards Lifesciences price target raised to $210 from $195 at Jefferies
Jefferies analyst Raj Denhoy raised his price target for Edwards Lifesciences to $210 from $195 saying the company remains well positioned for 10%-plus growth following its Q1 results. He sees 2019 as "another big year" in transcather therapies and keeps a Buy rating on the shares.
03/27/19
JPMS
03/27/19
NO CHANGE
Target $190
JPMS
Neutral
Edwards Lifesciences price target raised to $190 from $175 at JPMorgan
JPMorgan analyst Robbie Marcus raised his price target for Edwards Lifesciences to $190 from $175 and keeps a Neutral rating on the shares. The analyst says his doctor survey following the Annual Scientific Session is "very bullish" and supportive of "significant" transcatheter aortic valve replacement market growth in the U.S. Marcus expects TAVR volume growth to accelerate from 15% in 2018 to 19% in 2019 and 22% in 2020. Nonetheless, he remains Neutral on shares of Edwards at current valuation levels. The analyst wants to see evidence of a faster than expected acceleration in the U.S. market, or less share/price loss to competition before looking to revisit his rating.
03/27/19
ADAM
03/27/19
NO CHANGE
Target $215
ADAM
Buy
CMS' TAVR coverage memo positive for Edwards Lifesciences, says Canaccord
Canaccord analyst Jason Mills reiterated a Buy rating on Edwards Lifesciences with a $215 price target, telling investors in a research note that he views the Centers for Medicare and Medicaid Services' proposed Transcatheter Aortic Valve Replacement decision memo as incrementally positive for the TAVR field in general, and an incremental positive for Edwards specifically. The new, proposed TAVR coverage memo, which Mills says is less stringent on specific, prior procedure requirements, updates the requirements for TAVR centers to maintain their status as a TAVR center, and requires the center perform at least 50 AVRs/year, including at least 20 TAVRs/year, or else at least 100 AVRs every two years, at least 40 of which need to be TAVR.
MANH Manhattan Associates
$72.91

1.16 (1.62%)

04/22/19
RHCO
04/22/19
UPGRADE
Target $66
RHCO
Buy
Manhattan Associates rises after SunTrust upgrade to Buy on innovation optimism
As previously reported, SunTrust analyst Terry Tillman upgraded Manhattan Associates to Buy from Hold, telling investors in a note published prior to the open that he has become more positive on the company's innovation cycle and long-term dynamics for its cloud solutions. While he anticipates continued stabilizing and "at least in-line" trends through 2019, Tillman noted that his upgrade is not based on a call on Q1 results, which the company is scheduled to report after the close on Tuesday. In terms of specific product innovations that he is excited about, Tillman highlights innovation in the company's on-premise warehouse management system products and the portfolio of Active Omni cloud products. He increased his price target to $66 from $50 on Manhattan Associates shares, which are up 6.5% to $61.01 in early trading.
10/24/18
RHCO
10/24/18
NO CHANGE
Target $50
RHCO
Hold
Manhattan Associates price target lowered to $50 from $57 at SunTrust
SunTrust analyst Terry Tillman lowered his price target on Manhattan Associates to $50 and kept his Hold rating after its Q3 results, saying that the company's software license revenue was weaker than expected and may remain under pressure into 2019. Tillman notes that while the cloud transition is being "very well managed", the risk-reward on the stock justified a neutral rating.
10/24/18
BNCH
10/24/18
NO CHANGE
Target $60
BNCH
Buy
Manhattan Associates price target lowered to $60 from $69 at Benchmark
Benchmark analyst Mark Schappel said Manhattan Associates' Q3 played out largely as he expected with a mix of positives, such as cloud upside and an improving services business, along with a few negatives, like its license miss and lower cash flow from operations. While he continues to think Manhattan Associates should benefit from an improving retail environment and its product line refresh, he lowered his price target on the stock to $60 to account for the broader software selloff. Schappel keeps a Buy rating on Manhattan Associates shares.
04/22/19
RHCO
04/22/19
UPGRADE
RHCO
Buy
Manhattan Associates upgraded to Buy from Hold at SunTrust
SNAP Snap
$14.85

0.71 (5.02%)

07/23/19
07/23/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with a Buy at Rosenblatt, while Twitter (TWTR) was initiated with a Neutral. 2. Silicon Labs (SLAB) initiated with a Buy at Benchmark, while Intel (INTC) and Xilinx (XLNX) were initiated with Hold ratings. 3. Cambridge Bancorp (CATC) initiated with a Market Perform at Keefe Bruyette. 4. Broadcom (AVGO) assumed with an Outperform at RBC Capital. 5. Adaptive Biotechnologies (ADPT) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/22/19
STFL
07/22/19
UPGRADE
Target $17
STFL
Buy
Snap upgraded to Buy from Hold at Stifel
Stifel analyst John Egbert upgraded Snap to Buy and raised his price target to $17 from $13.
07/22/19
STFL
07/22/19
UPGRADE
Target $17
STFL
Buy
Snap upgraded to Buy from Hold at Stifel
Stifel analyst John Egbert upgraded Snap to Buy and raised his price target to $17 from $13 ahead of its Q2 earnings tomorrow, saying the company's sales reorganization efforts were already reflected in its prior guidance and the daily active user checks for the quarter appear to be positive. The analyst contends that if the impact of the reorganization is limited, the management's prior guidance may prove to be conservative, adding that Snap's advertising products with large brands and direct response advertisers appear to be gaining traction.
07/23/19
07/23/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Buy from Hold at Stifel with analyst John Egbert saying the company's sales reorganization efforts were already reflected in its prior guidance and the daily active user checks for the quarter appear to be positive. 2. Murphy Oil (MUR) upgraded to Buy from Neutral at Goldman Sachs with analyst Brian Singer saying he believes the company's free cash flow generation is being underappreciated by the market. 3. Karyopharm (KPTI) upgraded to Overweight from Neutral at JPMorgan with analyst Eric Joseph saying he conducted a U.S. physician survey assessing Xpovio anticipated use in the approved indication of penta-refractory myeloma, as well as expectations around use in earlier-line settings. The survey of 15 doctors data show favorable reception to Xpovio's clinical profile, with 75% respondents intending to write Xpovio for PR-MM within the next 12 months. 4. Smith & Nephew (SNN) upgraded to Buy from Hold at Berenberg with analyst Tom Jones saying he believes management and process changes have addressed the company's execution issues. He views Smith & Nephew's portfolio as "highly competitive." 5. Columbia Sportswear (COLM) upgraded to Buy from Neutral at BofA/Merrill with analyst Alexander Perry citing his outlook for the company to generate "significant near-term revenue and EPS upside" amid a strong wholesale environment for Columbia's apparel as well as its "significant" under-penetration in footwear. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TXN Texas Instruments
$120.05

1.89 (1.60%)

07/10/19
JEFF
07/10/19
NO CHANGE
JEFF
Texas Instruments, Analog Devices 'ownable' for next 4 cycles, says Jefferies
Jefferies analyst Mark Lipacis says shares of Analog Devices (ADI) and Texas Instruments (TXN) are "ownable" through the next four cycles. The analyst updated his "Analog Renaissance Report" and believes consolidation is "better and faster" than previously thought and that his three-to-five year earnings bull case is 50%/100% above 2019 consensus estimates.
07/08/19
KEYB
07/08/19
NO CHANGE
KEYB
Ambarella, Silicon Labs could be next as semiconductor M&A heats up, says KeyBanc
KeyBanc analyst John Vinh believes semiconductor M&A activity is starting to heat up again, and sees diversification into secular growth areas in IoT, automotive, and cloud, and increased scale and customer breadth, as key underlying deal drivers within the space. The analyst expects further consolidation to continue, but notes U.S./China political tensions and uncertainty regarding regulatory approvals could limit larger scale M&A. Companies that could be acquired next include Ambarella (AMBA) or Silicon Labs (SLAB), he contends, while expecting Broadcom (AVGO), Applied Materials (AMAT), Intel (INTC), NXP Semiconductors (NXPI), Skyworks (SWKS), Texas Instruments (TXN), and Xilinx (XLNX) to be the most acquisitive.
07/01/19
SBSH
07/01/19
NO CHANGE
SBSH
Citi sees semiconductor sector trading higher on lift of Huawei ban
Citi analyst Christopher Danely expects the semiconductor sector to trade higher after President Trump over the weekend lifted the ban on selling to Huawei and stated the U.S. would not go through with the additional $300B in tariffs. The analyst maintains his positive stance on the group and keeps a Buy ratings on Broadcom (AVGO), Microchip (MCHP), ON Semiconductor (ON) and Texas Instruments (TXN).
05/16/19
MSCO
05/16/19
NO CHANGE
MSCO
Micron, Skyworks, Qorvo among chipmakers exposed to Huawei, says Morgan Stanley
Following media reports discussing a potential ban of sales from U.S. companies to Huawei, Morgan Stanley analyst Joseph Moore identified semiconductor companies with exposure to the company, including Skyworks (SWKS), Qorvo (QRVO), Broadcom (AVGO), Analog Devices (ADI), ON Semiconductor (ON), Maxim (MXIM), Texas Instruments (TXN), Xilinx (XLNX), Micron (MU) and Inphi (IPHI). In his note, Moore recalled that a similar ban on ZTE (ZTCOY) last year was ultimately removed.
OLBK Old Line Bancshares
$26.14

(0.00%)

07/26/18
SDLR
07/26/18
DOWNGRADE
SDLR
Hold
Old Line Bancshares downgraded to Hold from Buy at Sandler O'Neill
Sandler O'Neill analyst Casey Whitman downgraded Old Line Bancshares citing valuation and maintained a $38 price target.
CSL Carlisle
$132.30

2.445 (1.88%)

06/18/19
OPCO
06/18/19
NO CHANGE
Target $155
OPCO
Outperform
Carlisle price target raised to $155 from $150 at Oppenheimer
Oppenheimer analyst Bryan Blair raised his price target for Carlisle to $155 from $150 after attending the Western Roofing Expo and coming away "incrementally confident in solid underlying commercial roofing demand." The analyst reiterates an Outperform rating on the shares.
04/24/19
OPCO
04/24/19
NO CHANGE
Target $150
OPCO
Outperform
Carlisle price target raised to $150 from $140 at Oppenheimer
Oppenheimer analyst Bryan Blair raised his price target for Carlisle to $150 from $140 following quarterly results. Given CCM's favorable 2019-2020 setup, CIT and CFT's accelerating self-help stories, capital deployment optionality across platforms, and Carlisle's resultant earnings/cash generation potential, the analyst believes shares have further room to run. He reiterates an Outperform rating on the shares.
07/08/19
BUCK
07/08/19
DOWNGRADE
BUCK
Neutral
Carlisle downgraded to Neutral from Buy at Buckingham
04/09/19
BARD
04/09/19
NO CHANGE
Target $134
BARD
Outperform
Buy Carlisle on weather-related weakness, says Baird
Baird analyst Timothy Wojs says the firm's Roofing Survey indicates that nonresidential roofing volume was up slightly year-over-year in the first quarter despite the negative impact of weather in select regions. Wojs tells investors in a research note that with Carlisle shares having done well year-to-date and that weather creates some modest moving parts in Q1, adding that he is not overly aggressive into the print, but says he would be a buyer of any weather-related Q1 weakness, given his view of reaccelerating EBIT, improved price-cost, and capital deployment over course of 2019. Wojs maintains an Outperform rating and $134 price target on Carlisle shares.
CMG Chipotle
$740.42

-1.88 (-0.25%)

07/19/19
NRCS
07/19/19
INITIATION
Target $400
NRCS
Sell
Chipotle reinstated with a Sell at Northcoast
Northcoast analyst Jim Sanderson reinstated coverage on Chipotle with a Sell and $400 price target.Target $400.
07/18/19
WEDB
07/18/19
NO CHANGE
Target $750
WEDB
Neutral
Chipotle price target raised to $750 from $700 at Wedbush
Wedbush analyst Nick Setyan raised his price target for Chipotle to $750 from $700 ahead of quarterly results, given accelerating transaction trends and improving unit economics. The analyst reiterates a Neutral rating on the shares.
07/15/19
PIPR
07/15/19
NO CHANGE
Target $824
PIPR
Overweight
Chipotle price target raised to $824 from $792 at Piper Jaffray
Piper Jaffray analyst Nicole Miller Regan raised her price target for Chipotle Mexican Grill to $824 from $792 following her checks in June and visit to the copay's London market. The analyst says that although the Chipotle investment thesis is focused on the domestic recovery and growth potential, she continues to believe in the long-term potential for an expanded international presence through accelerated company-owned development or franchise growth. She maintains her positive 8% same-store sales estimate for Q2 following June checks that suggested trends were "steady sequentially" in the high-single-digit range. Miller Regan reiterates her bullish stance on Chipotle with an Overweight rating.
07/15/19
WELS
07/15/19
NO CHANGE
Target $696
WELS
Market Perform
Chipotle price target raised to $696 from $647 at Wells Fargo
Wells Fargo analyst Jon Tower raised his price target for Chipotle to $696 from $647 ahead of quarterly results as he expects both the top and bottom lines to come in modestly better than expected. Nonetheless, Street EBITDA numbers are likely to remain intact for 2019 given avocado inflation, he contends, adding that he finds it difficult to argue for greater near-term upside potential for the shares given the stock's risk/reward. Tower reiterates a Market Perform rating on the shares.
CNI Canadian National
$91.05

-0.07 (-0.08%)

06/12/19
DBAB
06/12/19
NO CHANGE
DBAB
Deutsche lowers estimates for U.S. Class 1 Rails, keeps Buy ratings
Deutsche Bank analyst Amit Mehrotra lowered his Q2 earnings forecasts by 4% on average, taking him below consensus for all the U.S. Class 1 Rails - CSX (CSX), Kansas City Southern (KSU), Norfolk Southern (NSC) and Union Pacific (UNP). The analyst is in-line with the consensus for Canadian National (CNI) and above consensus for Canadian Pacific (CP). Despite the estimate cuts, Mehrotra remains positive on Rail stocks, reflecting the sector's "volume-agnostic" cost opportunity. He lowered his price target for CSX to $87 from $89, for Kansas City Southern to $138 from $142, for Norfolk Southern to $196 from $198 and for Union Pacific to $197 from $200. The analyst keeps Buy ratings on all four names.
06/13/19
LEHM
06/13/19
DOWNGRADE
Target $170
LEHM
Equal Weight
Union Pacific downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Brandon Oglenski downgraded Union Pacific (UNP) to Equal Weight from Overweight and lowered his price target for the shares to $170 from $190. The analyst also cut his Transportation sector view to Neutral saying he sees "real fundamental challenges set against high market expectations." Railroad equities are not properly discounting recent headwinds from softer demand and "lower supply chain urgency" across North America, Oglenski tells investors in a research note. Further, he sees increasing risk that tariff driven inflation could "damp consumer consumption" later this year, at least in the U.S. As a result, Oglenski suggests investors take some Transportation exposure off the table. He keeps Equal Weight ratings on Canadian National (CNI), Kansas City Southern (KSU) and Norfolk Southern (NSC) as well as Overweight ratings on Canadian Pacific (CP) and CSX (CSX).
07/10/19
GSCO
07/10/19
INITIATION
Target $97
GSCO
Neutral
Canadian National initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Jordan Alliger started Canadian National with a Neutral rating and $97 price target. The analyst cites the company's "industry-high" price-to-earnings valuation for his Neutral rating. He sees more relative upside in other rail names.
04/30/19
BMOC
04/30/19
NO CHANGE
Target $125
BMOC
Market Perform
Canadian National price target raised to $125 from $116 at BMO Capital
BMO Capital analyst Fadi Chamoun raised his price target on Canadian National to $125, saying its worse than expected Q1 results were due to the challenging winter weather. Instead, the analyst points to the management's maintained focus on investing in the company's capacity, leading to its growth and a "more favorable" operating leverage in the future. Chamoun keeps his Market Perform rating on Canadian National shares but adds that he would consider an upgrade with a greater margin of safety in valuation for the stock.
DFS Discover
$84.54

2.205 (2.68%)

05/07/19
05/07/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Fluor (FLR) downgraded to Neutral from Buy at Goldman Sachs with analyst Jerry Revich seeing an unclear medium-term margin outlook amid the company's CEO transition and further project writedowns in Q1. 2. Gardner Denver (GDI) downgraded to Neutral from Buy at UBS with analyst Damian Karas downgraded saying the shares are due for a "breather" following the recent run. 3. Boeing (BA) downgraded to Equal Weight from Overweight at Barclays with analyst David Strauss expecting the recovery of 737 Max production to take longer than expected. 4. Discover (DFS) downgraded to Perform from Outperform at Oppenheimer with analyst Dominick Gabriele seeing limited upside in the shares following the rally year-to-date now that his estimates are in-line with the consensus. 5. Cambrex (CBM) downgraded to Outperform from Strong Buy at First Analysis with analyst Steven Schwartz saying the company's valuation multiple is now in-line with peers following the recent share price appreciation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/08/19
DBAB
07/08/19
INITIATION
Target $87
DBAB
Hold
Discover reinstated with a Hold at Deutsche Bank
Deutsche Bank analyst Dave Rochester reinstated coverage of Discover Financial with a Hold rating and $87 price target.
05/07/19
OPCO
05/07/19
DOWNGRADE
OPCO
Perform
Oppenheimer downgrades Discover on limited upside after recent rally
Oppenheimer analyst Dominick Gabriele downgraded Discover Financial Services to Perform from Outperform without a price target. The analyst sees limited upside in the shares following the rally year-to-date now that his estimates are in-line with the consensus. While Discover's loan growth "could speed back up" and credit could be slightly better in 2019 relative to expectations, the stock's recent outperformance reflects this, Gabriele tells investors in a research note.
06/19/19
BOFA
06/19/19
INITIATION
Target $82
BOFA
Neutral
Discover reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Jason Kupferberg reinstated coverage of Discover Financial Services with a Neutral rating and $82 price target. The analyst believes cyclical credit concerns remain a "potent overhang" on the shares. As a result, he sees limited potential for multiple expansion from current stock levels.
NAVI Navient
$13.71

0.27 (2.01%)

01/16/19
JPMS
01/16/19
NO CHANGE
JPMS
JPMorgan resets ratings across Specialty Finance sector
The prospect of a prolonged government shutdown and global trade uncertainty threatens what has been "steady, reliable domestic growth," JPMorgan analyst Richard Shane tells investors in a research note on the Specialty Finance sector. Further, the analyst believes the outlook for Fed action has become more clouded. However, Shane thinks sentiment across his sector seems to reflect uncertainty, which gives him an "increasingly positive bias" to the group. He sees the most upside potential among consumer finance names, with late cycle uncertainty "potentially dampening" upside among commercial mortgage real estate investment trusts. Shane this morning upgraded a host of names: Navient (NAVI), OneMain Holdings (OMF) and KKR Real Estate Finance Trust (KREF) to Neutral from Underweight and TCG BDC (CGBD), Annaly Capital (NLY) and Apollo Commercial (ARI) to Overweight from Neutral. Today's downgrades are Santander Consumer (SC), BlackRock Capital Investment (BKCC), WhiteHorse Finance (WHF) to Underweight from Neutral along with PennantPark (PNNT) and Granite Point Mortgage (GPMT) to Neutral from Overweight.
01/16/19
JPMS
01/16/19
UPGRADE
Target $12
JPMS
Neutral
Navient upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Richard Shane upgraded Navient to Neutral while lowering his price target for the shares to $12 from $13.
04/25/19
JPMS
04/25/19
UPGRADE
Target $14.5
JPMS
Overweight
Navient upgraded to Overweight with $14.50 price target at JPMorgan
JPMorgan analyst Richard Shane upgraded Navient to Overweight from Neutral and raised his price target for the shares to $14.50 from $12.50. The analyst is encouraged by Navient's traction on new business initiatives following its guidance increase. Further, Shane says Navient is one of the few liability-sensitive companies that he covers and that the interest rate outlook now looks neutral to favorable.
04/25/19
JPMS
04/25/19
UPGRADE
Target $14.5
JPMS
Overweight
Navient upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Richard Shane upgraded Navient to Overweight from Neutral and raised his price target for the shares to $14.50 from $12.50.
WFC Wells Fargo
$47.20

0.7 (1.51%)

07/17/19
BMOC
07/17/19
NO CHANGE
Target $59
BMOC
Market Perform
Wells Fargo price target lowered to $59 from $63 at BMO Capital
BMO Capital analyst James Fotheringham lowered his price target on Wells Fargo to $59 and kept his Market Perform rating after its operating expense-driven miss in Q2. The analyst also lowers his FY19 and FY20 EPS views by 9c and 37c to $4.40 and $5.20 respectively given the bank's lower net interest income and higher costs. Fotheringham contands that although Wells Fargo shares trade "well below" their average historical multiples, value investors should stay away until there is an update on guidance from a permanent CEO and the Fed gives more clarity on the timing of potential lifting of the bank's asset cap.
07/17/19
07/17/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Micro Focus (MFGP) downgraded to Sell from Neutral at Goldman Sachs. 2. Wells Fargo (WFC) downgraded to Neutral from Outperform at Macquarie. 3. Alliance Resource Partners (ARLP) downgraded to Neutral from Buy at B. Riley FBR with analyst Lucas Pipes citing the company's "disappointing" sales volumes in Q2 for the downgrade. 4. 58.com (WUBA) downgraded to Neutral from Outperform at Credit Suisse. 5. Ralph Lauren (RL), Levi Strauss (LEVI), and PVH Corp. (PVH) downgraded to Sell from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/17/19
MACQ
07/17/19
DOWNGRADE
MACQ
Neutral
Wells Fargo downgraded to Neutral from Outperform at Macquarie
07/12/19
07/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) downgraded to Neutral from Buy at Citi. 2. Rexnord (RXN) was downgraded to Underperform from Buy at BofA/Merrill while Parker-Hannifin (PH) was downgraded to Neutral from Buy. 3. Instructure (INST) downgraded to Market Perform from Outperform at Raymond James with analyst Brian Peterson saying his rating change "in no way reflects any incremental concerns about the company's strategic direction," but is entirely about his more cautious view on 2020 growth projections. 4. MSC Industrial (MSM) downgraded to Neutral from Buy at Northcoast with analyst Tom Hayes citing the company's report of weaker than expected organic sales growth and margin headwinds in Q3. 5. Charles Schwab (SCHW) was downgraded to Neutral from Buy at BofA/Merrill and to Market Perform from Outperform at Keefe Bruyette. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
IRBT iRobot
$89.64

-2.7 (-2.92%)

04/25/19
PIPR
04/25/19
NO CHANGE
Target $96
PIPR
Overweight
iRobot needs 'big' second half to meet 2019 guidance, says Piper Jaffray
iRobot reported March quarter results that missed Street revenue expectations but comfortably beat on the bottom line thanks to a tax benefit, Piper Jaffray analyst Troy Jensen tells investors in a research note. Further, the Q1 sales softness was matched with an unexpected ramp in Q2 operating expenditures, which brought the Q2 earnings guidance well below consensus, adds the analyst. With the company reiterating 2019 guidance, this implies a "big" second half is needed to reach the company's goals and full year consensus expectations, says Jensen. The analyst, who has been Neutral on iRobot shares given valuation concerns, maintains his rating and $96 price target even after yesterday's selloff.
04/18/19
JPMS
04/18/19
NO CHANGE
Target $100
JPMS
Neutral
iRobot price target raised to $100 from $88 at JPMorgan
JPMorgan analyst Mark Strouse raised his price target for iRobot to $100 from $88 and keeps a Neutral rating on the shares ahead of the company's "seasonally slow" Q1 results. The analyst expects "continued strong results," though he expects iRobot to keep its revenue guidance unchanged. Management's tone is likely to remain optimistic, particularly regarding the pending launch of the lawnmower product, Terra, and regarding additional product launches later in 2019, Strouse tells investors in a research note. While his price target implies downside, the analyst does not view iRobot as a short as he expects investor optimism regarding new products to "buoy the stock near term."
06/10/19
RAJA
06/10/19
NO CHANGE
RAJA
iRobot estimates lowered at Raymond James on tariff increase
Raymond James analyst Brian Gesuale maintained a Market Perform rating on iRobot, but lowered his FY19 and FY20 EPS estimates on the stock due to Trump's latest tariff hike and the "lack of visibility that a resolution will materialize any time soon."
07/03/19
SBSH
07/03/19
NO CHANGE
SBSH
Spending trends favorable for Logitech, unfavorable for GoPro, says Citi
After surveying 75 retail and electronics stores in U.S. throughout June to inquire about promotions and sell-through, Citi analyst Asiya Merchant says spending trends are favorable for both Logitech (LOGI) and Corning (GLW) and unfavorable for GoPro (GPRO). Across categories, TVs stood out as the category most likely to be the top selling consumer electronics product and highest category to exceed sales expectations, while digital cameras are least likely to be a top seller and most likely to miss, Merchant tells investors in a research note. The analyst believes video gaming accessories trends are positive for Logitech while digital camera trends are negative for GoPro. The digital camera market is at historical lows, contends Merchant. The analyst keeps a Buy rating on Logitech shares with a $46 price target. She also lowered her price target for Neutral-rated iRobot (IRBT) to $95 from $100 to reflect the 25% tariff levied on robotic vacuums. Merchant adds that the survey yield "mixed" results for robotic vacuums.
RHI Robert Half
$58.81

1.45 (2.53%)

04/25/19
BMOC
04/25/19
NO CHANGE
Target $62
BMOC
Market Perform
Robert Half price target lowered to $62 from $68 at BMO Capital
BMO Capital analyst Jeffrey Silber lowered his price target on Robert Half to $62 and kept his Market Perform rating after its Q1 earnings miss, driven by decelerating revenues. The analyst notes slowing growth in most of the company's major segments amid "tougher comps,European slowing growth and more selective US clients."
04/16/19
RBCM
04/16/19
INITIATION
Target $71
RBCM
Sector Perform
Robert Half initiated with a Sector Perform at RBC Capital
RBC Capital analyst Seth Weber initiated Robert Half with a Sector Perform rating and a price target of $71. The analyst says that it is "hard to argue" with the company's "impressive return on invested capital" and "attractive position", but he also sees the stock becoming less attractive relative to "other staffers" after its strong last-twelve-months and year-to-date performance. Given his anticipated scenario of a slowing macro revenue trajectory, Weber sees Robert Half shares moving "closer to fair value".
01/23/19
NRCS
01/23/19
NO CHANGE
Target $45
NRCS
Sell
Robert Half price 'too high', Kelly Services 'attractive', says Northcoast
Northcoast analyst John Healy is keeping his Sell rating and $45 price target on Robert Half (RHI) as part of his broader research note on staffing companies, saying that while business activity in Q4 was in growth mode with a 5.2% reported rate of increase, he sees its stock price as too high. Healy adds that Robert Half's longer term competitive dynamics and margin profile are concerning. The analyst has a positive view on Kelly Services (KELYA) from a risk-reward perspective however, keeping his Buy rating and $31 price target on the shares, as he sees the stock price trading below its intrinsic value.
01/30/19
RHCO
01/30/19
NO CHANGE
Target $70
RHCO
Hold
Robert Half price target lowered to $70 from $76 at SunTrust
SunTrust analyst Tobey Sommer lowered his price target on Robert Half to $70 after its Q4 results, saying that while the company generated higher margins and matched strong consulting demand with higher staff count of its own, he remains concerned by the revenue impact from the slowing macro data in Europe. The analyst kept his Hold rating on Robert Half, even though he is "intrigued by the company's cross-selling consulting and staffing services as a significant potential long-term driver of growth." Sommer also raised his FY19 EPS outlook by 6c to $4.00, adding that the ROIC for Q4 was a standout and "reflects the long term organic growth story" at Robert Half.
V Visa
$180.89

0.34 (0.19%)

07/10/19
WELS
07/10/19
NO CHANGE
Target $200
WELS
Outperform
Visa price target raised to $200 from $181 at Wells Fargo
Wells Fargo analyst Donald Fandetti raised his price target for Visa to $200 from $181 ahead of quarterly results as he expects "meet and beats" into earnings from the card networks and issuers, as the U.S. consumer data points he tracks are holding up well. The analyst reiterates an Outperform rating on the shares.
07/18/19
JEFF
07/18/19
INITIATION
Target $210
JEFF
Buy
Visa assumed with a Buy at Jefferies
Jefferies analyst Trevor Williams assumed coverage of Visa with an unchanged Buy rating and raised his price target for the shares to $210 from $190.
07/11/19
DBAB
07/11/19
NO CHANGE
Target $225
DBAB
Buy
Visa price target raised to $225 from $177 at Deutsche Bank
Deutsche Bank analyst Bryan Keane raised his price target for Visa to $225 from $177 and reiterates a Buy rating on the shares. Although the payment networks have a long runway to benefit from the secular growth of card-based transactions, the expanding market share opportunity into new account-to-account payment flows and non-interchange based revenue models are being underappreciated, Keane tells investors in a research note.
06/19/19
MSCO
06/19/19
NO CHANGE
MSCO
Visa, MasterCard disruption threat from Libra 'fairly low,' says Morgan Stanley
After Facebook (FB) unveiled its cryptocurrency Libra yesterday, Morgan Stanley analysts led by Brian Nowak highlighted six "key questions" they still have about the impact on Facebook, commerce and the overall global banking and payments system from the social media giant's offering. The team, as previously stated, believe that Instagram commerce could be a greater than $4B annual opportunity for Facebook and even larger over the long term across Instagram, Messenger, WhatsApp and the core app. However, they also think costs may rise as they believe Facebook is likely going to have to fund rewards to drive Libra adoption. Libra's real-time aspect largely already exists in the banking system, except for in real-time cross-border payments, which is a challenge that Facebook could address, though it won't be alone there as JPMorgan (JPM) is also working on its own s Interbank Information Network blockchain, the team noted. The team believes Libra's threat of disruption to Visa (V) and Mastercard (MA) is "fairly low" as the major networks have a significant scale advantage, low costs, mature fraud detection abilities and they are both also founding members and investors, Nowak and the analysts also noted.
SGEN Seattle Genetics
$75.88

-0.22 (-0.29%)

07/18/19
DBAB
07/18/19
INITIATION
Target $79
DBAB
Hold
Seattle Genetics initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Konstantinos Aprilakis started Seattle Genetics with a Hold rating and $79 price target. The analyst initiated coverage on eight smid-cap Biotechnology stocks in the oncology space.
07/17/19
PIPR
07/17/19
UPGRADE
Target $75
PIPR
Overweight
Seattle Genetics upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro upgraded Seattle Genetics to Overweight from Neutral and raised his price target for the shares to $75 from $64. The company reported Q2 Adcetris revenue of $159M, beating consensus of $149M and reversing the trend of low single-digit quarter-over-quarter growth observed over the last three quarters, Catanzaro tells investors in a research note. Further, the analyst's survey work and conversations with key opinion leaders suggests that enfortumab vedotin is poised to see strong uptake in post-chemo/check-point inhibitors UBC. He believes Seattle Genetics' 2019 guidance of $610M-$640M is "well within reach" while it has the opportunity to report positive data from multiple potential registration trials over the next 12 months.
04/10/19
STFL
04/10/19
INITIATION
Target $70
STFL
Hold
Seattle Genetics initiated with a Hold at Stifel
Stifel analyst Stephen Willey initiated Seattle Genetics with a Hold rating and a price target of $70, saying that while the company "commands a leadership position in the development of antibody-drug conjugate technology", the current ADCETRIS estimates as "much-too-optimistic" in suggesting trajectory to sales of over $1B. The analyst adds that although the "recently-announced phase data for enfortumab vedotin will initiate Seattle Genetics' transition to a multi-product commercial company", he sees the "presumption of clinical/commercial success to be appropriately risk-adjusted in the stock at these levels."
04/25/19
PIPR
04/25/19
NO CHANGE
Target $64
PIPR
Neutral
Seattle Genetics Q1 marks third quarter of 'sluggish growth', says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro is keeping his Neutral rating and $64 price target on Seattle Genetics after its Q1 results that saw Adcetris sales of $135M missing consensus of $141M. The analyst notes that this marks the 3rd consecutive quarter of "sluggish growth", also lowering his FY19 EPS outlook to ($1.05) from (94c) and FY20 outlook to (14c) from 12c. Catanzaro lowers his FY19 Adcetris sales forecast to $611M from $633M, adding that the company's Adcentris revenue outlook of $610M-$640M for this year may "prove difficult."
FB Facebook
$202.38

0.06 (0.03%)

07/22/19
FBCO
07/22/19
NO CHANGE
Target $235
FBCO
Outperform
Facebook's resources to focus more on product development, say Credit Suisse
Credit Suisse analyst Stephen Ju expects 2019 to mark the beginning of when Facebook's resources/capital allocation will be focused more on product development versus housecleaning. While the Libra announcement invited incremental regulatory scrutiny, the analyst does not view its ultimate success or failure to be material to his investment thesis for now. From a more near-term tactical perspective, his checks with advertisers suggest minimal deceleration for U.S. budgets coupled with ongoing headwinds in Europe. Ju reiterates an Outperform rating and a $235 price target on the shares
07/22/19
CLVD
07/22/19
NO CHANGE
CLVD
Buy
Facebook ad spending finished strong in Q2, says Cleveland Research
Cleveland Research analyst Chandler Converse said his checks point to a strong finish to Q2 at Facebook in terms of ad spending and he is maintaining his above consensus estimates based on his field work. The analyst, who believes better Stories performance is driving improved ROI for advertisers, sees upside to consensus estimates through 2019. Converse has a Buy rating on Facebook shares.
07/22/19
BARD
07/22/19
NO CHANGE
BARD
Marketing agency says social media spending reaccelerated in Q2, says Baird
Baird analyst Colin Sebastian noted that Kenshoo hosted an update call on Q2 online advertising trends, during which the digital marketing agency said social media spending increased 37% year-over-year. Sebastian noted this would be a reacceleration from 27% growth in Q1, adding that Kenshoo highlighted some advertiser feedback suggested a reacceleration of core Facebook (FB) advertising growth. The analyst, who believes this could drive upside to Q2 revenue estimates for Facebook, keeps an Overweight rating on the shares. Sebastian also highlighted that fundamental trends across search and social e-commerce advertising look healthy, which he believes suggests that Amazon's (AMZN) advertising growth is "likely incremental rather than cannibalistic."
07/23/19
BMOC
07/23/19
NO CHANGE
Target $195
BMOC
Market Perform
Facebook price target lowered to $195 from $200 at BMO Capital
BMO Capital analyst Daniel Salmon lowered his price target on Facebook to $195 and kept his Market Perform rating ahead of its Q2 earnings. The analyst says that while the quarter's results will likely be "strong", the ad targeting headwinds stemming from more user opt-outs and 3rd party platform changes should see revenue growth decelerating through Q1 of 2020 before recovering in Q2 as demand and pricing of the company's Stories platform ramp. Salmon warns if ad targeting capabilities are hindered more "materially", the expected revenue acceleration may be "prolonged".
TWTR Twitter
$37.90

0.32 (0.85%)

07/22/19
RSBL
07/22/19
INITIATION
Target $38
RSBL
Neutral
Twitter initiated with a Neutral at Rosenblatt
Rosenblatt analyst Mark Zgutowicz started Twitter with a Neutral rating and $38 price target. The analyst believes Twitter's "platform shortcomings" to direct response limit its future scale. Further, the 2020 election creates risk to the company's future daily active user growth as President Trump has heavily influenced engagement, Zgutowicz tells investors in a research note. More near term, the analyst points out the Twitter's revenue comparisons in the second half of 2019 are tougher than in the first half of the year.
07/17/19
KEYB
07/17/19
NO CHANGE
KEYB
KeyBanc expects 'solid results' from Alphabet, Facebook
KeyBanc analyst Andy Hargreaves believes ad spending across the major internet platforms remained "solid" in Q2 and expects positive results in the space. Feedback from advertisers through the quarter was positive on Facebook (FB) and Twitter (TWTR), where the analyst expects results to meet or exceed expectations. His checks were more mixed on Alphabet (GOOGL), though he still expects "solid" results with stabilization in revenue. Hargreaves continues to recommend owning Alphabet and Facebook.
07/23/19
BMOC
07/23/19
NO CHANGE
Target $42
BMOC
Market Perform
Twitter's delayed cost activities to weigh on margins, says BMO Capital
BMO Capital analyst Daniel Salmon kept his Market Perform rating and $42 price target on Twitter ahead of its Q2 results, saying the company's margins should be pressured in the quarter and for the balance of 2019 because of the management's "delayed cost activity". The analyst says Twitter has already guided 20% annual expense growth in 2019, but he sees potential for incremental safety and security spending to weigh on earnings.
AMZN Amazon.com
$1,994.44

8.51 (0.43%)

07/22/19
WEDB
07/22/19
NO CHANGE
Target $2350
WEDB
Outperform
Wedbush expects Amazon to report Q2 upside to 'conservative' profit guidance
Ahead of Amazon's Q2 results, Wedbush analyst Michael Pachter says he expects Q2 upside relative to exceedingly conservative profit guidance. The analyst believes Amazon can deliver substantial earnings over the long term by growing spending more slowly than revenues. Amazon Web Services, Fulfillment by Amazon, and ads should drive steady margin growth, with Prime driving overall retail revenue growth, he contends. Pachter has an Outperform rating and a $2,350 price target on the shares.
07/23/19
CHLM
07/23/19
NO CHANGE
Target $55
CHLM
Buy
Zillow weakness on Realogy-Amazon deal a buying opportunity, says Craig-Hallum
Craig-Hallum analyst Brad Berning said headlines about Amazon's (AMZN) newly-announced partnership with Realogy (RLGY) will spur increased fear of near-term competition in the personal real estate market, but he is skeptical that people will go to Amazon.com to search for a realtor or homes in any meaningful scale and views related weakness in shares of Zillow (ZG) as a buying opportunity. For Realogy, he thinks this "TurnKey" partnership is "desperation to improve their broker platform," which Berning sees having structural headwinds and a levered balance sheet. He maintains a Buy rating and $55 price target on shares of Zillow Group, which are down $1.73, or 3.7%, to $45.44 in pre-market trading.
07/23/19
BMOC
07/23/19
NO CHANGE
Target $2250
BMOC
Outperform
Amazon.com Q3 consensus may not reflect heavy seasonal spend, says BMO Capital
BMO Capital analyst Daniel Salmon warns that Amazon's operating income outlook for Q3 may miss expectations since consensus does not appear to "properly reflect" the quarter being a typical heavy investment period, adding to the company's continued spending on its one-day shipping efforts. The analyst also keeps his "structural" Outperform rating and $2,250 price target on Amazon, saying he would be a buyer on any stock price pullback thanks to its "positive revenue mix shift" with higher-margin businesses like AWS.
GOOG Alphabet
$1,146.62

8.53 (0.75%)

07/17/19
SBSH
07/17/19
INITIATION
Target $39
SBSH
Neutral
Slack Technologies initiated with a Neutral at Citi
Citi analyst Walter Pritchard started Slack Technologies (WORK) with a Neutral rating and $39 price target. Both Microsoft (MSFT) and Alphabet (GOOGL) see the productivity and collaboration software category as a strategic imperative and are investing, which will keep competitive pressure on Slack, Pritchard tells investors in a research note.
07/09/19
LEHM
07/09/19
NO CHANGE
Target $1315
LEHM
Overweight
Alphabet sentiment too negative into Q2 results, says Barclays
Barclays analyst Ross Sandler believes the sentiment on Alphabet shares "seems too negative" heading into the company's Q2 results. The analyst expects broadly in-line revenue and earnings in Q2, which he notes "tends to be not-good-enough for its stock performance." However, the buyside is expecting weakness, hence sentiment has "soured meaningfully," Sandler tells investors in a research note. He believes his channel checks are slightly more upbeat than what the investment community seems to be expecting. As a result, the backdrop for shares "is somewhat favorable for longer term investors," he says. Sandler keeps an Overweight rating on Alphabet with a $1,315 price target.
07/11/19
BNCH
07/11/19
NO CHANGE
Target $48
BNCH
Buy
OpenText price target raised to $48 from $42 at Benchmark
Benchmark analyst Mark Schappel raised his price target on OpenText (OTEX) shares to $48 from $42 after having attended the company's annual user conference. No "monumental revelations" came out of the event, but it reinforced his Buy rating and overall investment thesis, said Schappel, who sees the company as a consolidator in the relatively mature ECM/EIM software space. Ahead of April 2020, when the company will start to sell all of its solutions as a cloud service, OpenText "strengthened its cloud credentials" by announcing an extended partnership with Google Cloud to become Google's (GOOGL) preferred EIM services provider, noted Schappel.

TODAY'S FREE FLY STORIES

CBS

CBS

$43.83

0.5 (1.15%)

, VIA

Viacom

$27.27

-0.4 (-1.45%)

08:03
08/17/19
08/17
08:03
08/17/19
08:03
Periodicals
Viacom-CBS merger got panned by investors, Barron's says »

CBS (CBS) and Viacom…

CBS

CBS

$43.83

0.5 (1.15%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

VIAB

Viacom

$26.02

0.09 (0.35%)

AAPL

Apple

$206.44

4.71 (2.33%)

DIS

Disney

$135.19

1.79 (1.34%)

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

NFLX

Netflix

$302.74

6.81 (2.30%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

  • 27

    Oct

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

07:57
08/17/19
08/17
07:57
08/17/19
07:57
Periodicals
Myriad Genetics stock might have an FDA issue, Barron's says »

Myriad Genetics plunged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CSCO

Cisco

$46.96

0.73 (1.58%)

, NTAP

NetApp

$46.75

0.33 (0.71%)

07:50
08/17/19
08/17
07:50
08/17/19
07:50
Periodicals
Trade war hitting tech stocks, Barron's says »

Cisco (CSCO) plunged 9% a…

CSCO

Cisco

$46.96

0.73 (1.58%)

NTAP

NetApp

$46.75

0.33 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

  • 10

    Oct

  • 13

    Nov

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

, RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

07:47
08/17/19
08/17
07:47
08/17/19
07:47
Periodicals
Investors should not abandon oil, gas stocks, Barron's says »

Energy stocks have rarely…

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

CVX

Chevron

$115.79

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 25

    Sep

TGT

Target

$84.20

1.67 (2.02%)

, WMT

Walmart

$112.99

0.32 (0.28%)

07:40
08/17/19
08/17
07:40
08/17/19
07:40
Periodicals
Grocery Outlet thriving as rivals struggle, Barron's says »

While Dow was down 800…

TGT

Target

$84.20

1.67 (2.02%)

WMT

Walmart

$112.99

0.32 (0.28%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

AEO

American Eagle

$15.40

0.63 (4.27%)

07:33
08/17/19
08/17
07:33
08/17/19
07:33
Periodicals
American Eagle to soar despite trade war, Barron's says »

American Eagle's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 25

    Sep

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

, MTCH

Match Group

$84.53

2.08 (2.52%)

07:27
08/17/19
08/17
07:27
08/17/19
07:27
Periodicals
Dating business might be IAC's best asset, greatest challenge, Barron's says »

IAC (IAC) has rallied 34%…

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

MTCH

Match Group

$84.53

2.08 (2.52%)

IAC

IAC

$249.17

4.21 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 10

    Oct

AAPL

Apple

$206.44

4.71 (2.33%)

, HAS

Hasbro

$114.29

1.13 (1.00%)

07:13
08/17/19
08/17
07:13
08/17/19
07:13
On The Fly
Week in review How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$206.44

4.71 (2.33%)

HAS

Hasbro

$114.29

1.13 (1.00%)

MAT

Mattel

$10.74

(0.00%)

AGR

Avangrid

$49.29

0.37 (0.76%)

JPM

JPMorgan

$107.73

2.52 (2.40%)

BAC

Bank of America

$27.04

0.79 (3.01%)

C

Citi

$63.46

2.13 (3.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 27

    Oct

NCLH

Norwegian Cruise Line

$50.48

1.38 (2.81%)

18:04
08/16/19
08/16
18:04
08/16/19
18:04
Hot Stocks
Norwegian Cruise Line CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$27.12

0.14 (0.52%)

18:01
08/16/19
08/16
18:01
08/16/19
18:01
Hot Stocks
Regional Management CFO buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

RTN

Raytheon

$178.10

-0.42 (-0.24%)

17:59
08/16/19
08/16
17:59
08/16/19
17:59
Hot Stocks
Raytheon awarded $199.59M Navy contract for MK 15 CIWS »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$19.94

0.16 (0.81%)

17:57
08/16/19
08/16
17:57
08/16/19
17:57
Hot Stocks
Breaking Hot Stocks news story on Wendy's »

Trian Fund lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BRY

Berry Petroleum

$8.59

0.39 (4.76%)

17:54
08/16/19
08/16
17:54
08/16/19
17:54
Syndicate
Breaking Syndicate news story on Berry Petroleum »

Berry Petroleum files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSWI

CSW Industrials

$70.20

1.92 (2.81%)

17:52
08/16/19
08/16
17:52
08/16/19
17:52
Hot Stocks
CSW Industrials CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$3.03

0.135 (4.66%)

17:49
08/16/19
08/16
17:49
08/16/19
17:49
Hot Stocks
Oasis Petroleum CEO buys 30K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EE

El Paso Electric

$66.41

0.005 (0.01%)

17:45
08/16/19
08/16
17:45
08/16/19
17:45
Hot Stocks
El Paso Electric director Wertheimer sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$165.07

2.81 (1.73%)

17:42
08/16/19
08/16
17:42
08/16/19
17:42
Hot Stocks
Honeywell CEO sells 7.1K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBRX

Moleculin Biotech

$1.08

0.01 (0.93%)

17:37
08/16/19
08/16
17:37
08/16/19
17:37
Earnings
Moleculin Biotech reports Q2 EPS (3c), two estimates (10c) »

CFO Jonathan Foster…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVE

Viveve

$0.13

0.0046 (3.59%)

17:35
08/16/19
08/16
17:35
08/16/19
17:35
Syndicate
Breaking Syndicate news story on Viveve »

Viveve files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGO

Perrigo

$46.21

0.535 (1.17%)

17:30
08/16/19
08/16
17:30
08/16/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Perrigo »

Starboard lowers Perrigo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

UAL

United Continental

$82.96

1.36 (1.67%)

17:28
08/16/19
08/16
17:28
08/16/19
17:28
Hot Stocks
United Continental director Shapiro buys 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

  • 23

    Sep

MBIO

Mustang Bio

$3.88

0.19 (5.15%)

17:26
08/16/19
08/16
17:26
08/16/19
17:26
Syndicate
Breaking Syndicate news story on Mustang Bio »

Mustang Bio files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

BCLI

BrainStorm

$3.63

0.055 (1.54%)

17:24
08/16/19
08/16
17:24
08/16/19
17:24
Syndicate
Breaking Syndicate news story on BrainStorm »

BrainStorm files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLK

Westlake Chemical

$61.27

0.66 (1.09%)

17:15
08/16/19
08/16
17:15
08/16/19
17:15
Hot Stocks
Westlake Chemical raises quarterly dividend by 5% to 26.25c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIG

GigCapital

$10.30

(0.00%)

17:10
08/16/19
08/16
17:10
08/16/19
17:10
Hot Stocks
GigCapital receives noncompliance notice from NYSE »

GigCapital announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.